Product Description

Sotorasib (AMG 510) is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. In December 2019, it was approved to begin Phase 2 clinical trials.

Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and sotorasib is the first drug candidate to target this mutation, there have been high expectations for the drug.The Food and Drug Administration has granted a fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma with the G12C KRAS mutation.

Function
AMG-510 is a KRAS G12C inhibitor. Because it interrupts protein signaling, it causes KRAS G12C tumor regression.

Other hot selling peptides

Q1: Can i get small sample?
A: Yes, we can supply the free sample, but the shipping cost be paid by our customers.

Q2: How to start orders or make payments?
A: Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T, Western Union or Bitcoin or Escrow(Alibaba).

Q3:What's your MOQ?
A:Our MOQ is 1kg. But usually we accept less quantity such as 50g,100g on the condition that sample charge is 100% paid.

Q4:How about the packing?
A: Usually we provide the packing as 25kg/ bag/ carton/ drum. And we also can according to your requirment.

Q5: How about delivery leadtime?
A:About 3-5 working days after receipt of your payment

Q6: How to contact us?
A:You can chat with us by Trademanager&Skype Online. You can choose your interested products and send inquiry to us.Send Email to us.

Contact Us